openPR Logo
Press release

CRISPR/Cas9 - Request a FREE Sample for Your Genome Editing Research

09-09-2016 09:27 AM CET | Science & Education

Press release from: MoBiTec GmbH

CRISPR/Cas9 Genome Editing

CRISPR/Cas9 Genome Editing

The use of CRISPR/Cas9 has emerged as a powerful method for genome editing that can be delivered in multiple formats. MoBiTec together with Mirus Bio provide solutions to address delivery of Cas9 and guide RNA in plasmid, RNA, or RNP format.

Bacteria and archaea exhibit chromosomal elements called clustered regularly interspaced short palindromic repeats (CRISPR) that are part of an adaptive immune system that protects against invading viral and plasmid DNA. In Type II CRISPR systems, CRISPR RNAs (crRNAs) function with trans-activating crRNA (tracrRNA) and CRISPR-associated (Cas) proteins to introduce double-stranded breaks in target DNA. Target cleavage by Cas9 requires base pairing between the crRNA and tracrRNA as well as base pairing between the crRNA and the target DNA (see figure CRISPR/Cas9 Genome Editing). Target recognition is facilitated by the presence of a short sequence called a protospacer-adjacent motif (PAM) that conforms to the sequence NGG.

The bacterial CRISPR/Cas9 system has been adapted to serve as a versatile platform for RNA-directed genome editing in mammalian cells. The Cas9 endonuclease can be programmed by a dual RNA (crRNA and tracrRNA), or the core components of these RNAs can also be combined into a single hybrid guide RNA. Once Cas9 has cleaved the target DNA, two endogenous repair mechanisms, non-homologous end joining (NHEJ) and homology-directed repair (HDR), are triggered in response to the DNA break. The features of these DNA break repair pathways can be exploited to generate gene knock-outs or introduce defined modifications at the site of cleavage. NHEJ is an error-prone process that frequently results in the formation of small insertions and deletions that disrupt gene function. HDR requires homologous DNA as a template for repair and can be leveraged to create a limitless variety of modifications specified by the introduction of donor DNA containing the desired sequence flanked on either side by sequences bearing homology to the target.

The simplicity of using a noncoding RNA guide to target DNA for site-specific cleavage provides a distinct advantage over alternative genome editing technologies such as ZFNs and TALENs. Using the CRISPR/Cas9 strategy, retargeting the nuclease complex only requires introduction of a new RNA sequence and there is no need to reengineer the specificity of DNA-binding proteins.

Request a FREE Sample for Your Genome Editing Research

TransIT-X2® Dynamic Delivery System

• A novel, polymeric system for delivery of multiple nucleic acids to mammalian cells. Delivers CRISPR/Cas9 components in the following formats:

• DNA – Deliver plasmid DNA expressing Cas9 or guide RNA
• Guide RNA – Deliver guide RNA oligonucleotides targeting your gene of interest
• RNP – Deliver Cas9/guide RNA ribonucleoprotein complexes

TransIT®-mRNA Transfection Kit

• A high-efficiency, low toxicity transfection reagent for mammalian cells. Delivers CRISPR/Cas9 components in the following formats:

• mRNA – Deliver messenger RNA expressing Cas9
• Guide RNA – Deliver guide RNA targeting your gene of interest

Ingenio® Electroporation Solution

• A high-efficiency electroporation solution compatible with most conventional electroporation devices, including Lonza-Amaxa®, Bio-Rad®, or Harvard BTX®. Delivers CRISPR/Cas9 components in the following formats:

• DNA – Deliver plasmid DNA expressing Cas9 or guide RNA
• mRNA– Deliver messenger RNA expressing Cas9
• Guide RNA– Deliver guide RNA oligonucleotides targeting your gene of interest
• RNP– Deliver Cas9/guide RNA ribonucleoprotein complexes

Visit Us for More Information:

http://www.mobitec.com/cms/products/bio/02_genomics/crispr-cas-transfection-sample-request.html

Prove It to Yourself!

• * Sample Policy: MoBiTec together with Mirus considers sample requests for up to three different transfection products and one electroporation product per laboratory IN GERMANY (please contact us if from a different country). Please include all samples to be tested in a single request and mail to: info@mobitec.com

About MoBiTec GmbH

MoBiTec GmbH (Goettingen, Germany) is a privately held company, founded in 1987, that offers research tools for molecular and cell biology. Products include DNA vectors for cloning and expression, cell transfection reagents and cell culture tools, immobilized and soluble enzymes, products for genomics, proteomics, lipidomics, and glycomics research, numerous antibodies and recombinant proteins, superior fluorescence reagents and kits, affinity chromatography products, as well as general laboratory equipment.

In parallel to its own product lines, MoBiTec distributes products from international companies in Germany. MoBiTec products are distributed worldwide, in Germany from their home office, in other countries by distributors.

MoBiTec GmbH
Lotzestr. 22a
37083 Goettingen, Germany
www.mobitec.com
info@mobitec.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release CRISPR/Cas9 - Request a FREE Sample for Your Genome Editing Research here

News-ID: 361570 • Views:

More Releases from MoBiTec GmbH

FerroFarRed - An Ion Indicator for the Specific Detection of Fe2+
FerroFarRed - An Ion Indicator for the Specific Detection of Fe2+
Intracellular Fe2+ can react with hydrogen peroxide, thereby producing the hydroxyl radical, a reactive oxygen species (ROS). Excessive ROS causes oxidative stress, resulting in cancer and neurodegenerative diseases. FerroFarRed (also known as SiRhoNox-1 or ER-SiRhoNox) is a fluorescent probe,manufactured by Goryo Chemical, Japan, distributed in Europe by MoBiTec GmbH, Germany. FerroFarRed specifically detects labile iron (II) ions (Fe2+) and is known to react with Fe2+ only, separately from other metal
TransIT-VirusGEN® Transfection Reagent - Ideal for Recombinant Adeno-associated Virus Production
TransIT-VirusGEN® Transfection Reagent - Ideal for Recombinant Adeno-associated …
TransIT-VirusGEN® Transfection Reagent by Mirus, USA, is designed to enhance delivery of packaging and transfer vectors to adherent and suspension HEK 293 cell types to increase recombinant adeno-associated virus (AAV) and lentivirus production. Adeno-associated virus (AAV) is a nonenveloped, single stranded DNA virus from the Paroviridae family notable for its lack of pathogenicity, low immunogenicity and ability to infect both dividing and quiescent cells. Because AAV is replication-defective in the
Elabscience's Vast Portfolio of Products for Life Science Research Distributed by MoBiTec Germany
Elabscience's Vast Portfolio of Products for Life Science Research Distributed b …
MoBiTec's most recent select partner Elabscience specializes in immunodiagnostic technology for the life science community, offering a complete platform for R&D and manufacture. Elabscience major products cover Proteins, Antibodies, ELlSA Kits, CLIA Kits, Labeling Kits,Biochemical Kits, Cell Lines, and Other Reagents. Elabscience also offers custom services for customers, including Protein Expression and Purification Service, Custom Antibody Service, Custom ELISA Service, Cell Biology Service, Molecular Biology Service, and Whole Research Project Solutions. Every
MoBiTec to Exhibit at Potsdam Days on Bioanalysis 2018, Taking Place in Potsdam, Germany
MoBiTec to Exhibit at Potsdam Days on Bioanalysis 2018, Taking Place in Potsdam, …
The "Potsdam Days on Bioanalysis" provide an excellent platform for researchers, clinicians, and entrepreneurs to discuss diagnostics' hot topics, trends, and recent developments as well as new areas of application and future markets. Often, the implementation of goal-oriented and profitable cooperations is quite a challenge, in particular when it comes to innovative product developments in the fields of diagnostics and analytics. Typically, challenges lie within finding the right cooperation partners, identifying

All 5 Releases


More Releases for RNA

Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand. Browse 156 Market Data Tables and 112 Figures spread through 175
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited. Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year. Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018! Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and